Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
GLSI Stock Forecast 2025-2026
$8.94
Current Price
$123.86M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to GLSI Price Targets
+403.4%
To High Target of $45.00
+403.4%
To Median Target of $45.00
+403.4%
To Low Target of $45.00
GLSI Price Momentum
+2.4%
1 Week Change
+3.2%
1 Month Change
-34.6%
1 Year Change
-20.4%
Year-to-Date Change
-38.2%
From 52W High of $14.47
+14.9%
From 52W Low of $7.78
📊 TOP ANALYST CALLS
Did GLSI Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Greenwich LifeSciences is one of their latest high-conviction picks.
Latest GLSI Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, GLSI has a bullish consensus with a median price target of $45.00 (ranging from $45.00 to $45.00). The overall analyst rating is N/A (N/A/10). Currently trading at $8.94, the median forecast implies a 403.4% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
GLSI Analyst Ratings
1
Buy
0
Hold
0
Sell
GLSI Price Target Range
Low
$45.00
Average
$45.00
High
$45.00
Current: $8.94
Latest GLSI Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for GLSI.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 21, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $39.00 |
| Feb 11, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $38.00 |
| Aug 23, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $38.00 |
| May 22, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $36.00 |
| Feb 28, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $36.00 |
| Feb 20, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $36.00 |
| Apr 10, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $38.00 |
| Sep 1, 2021 | HC Wainwright & Co. | Yi Chen | Buy | Initiates | $78.00 |
| Jan 27, 2021 | Aegis Capital | Buy | Initiates | $N/A | |
| Jan 26, 2021 | Aegis Capital | Buy | Initiates | $N/A |
Greenwich LifeSciences Inc. (GLSI) Competitors
The following stocks are similar to Greenwich LifeSciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
GLSI
Greenwich LifeSciences
mkt cap
123.86M
Greenwich LifeSciences Inc. (GLSI) Financial Data
Greenwich LifeSciences Inc. has a market capitalization of $123.86M with a P/E ratio of -7.4x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -543.4%.
Valuation Metrics
Market Cap
$123.86M
Enterprise Value
$120.05M
P/E Ratio
-7.4x
PEG Ratio
-0.1x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+3.1%
Current Ratio
2.3x
Debt/Equity
0.0x
ROE
-543.4%
ROA
-254.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Greenwich LifeSciences Inc. (GLSI) Business Model
About Greenwich LifeSciences Inc.
What They Do
Develops immunotherapy treatments for breast cancer.
Business Model
Greenwich LifeSciences generates revenue by advancing its immunotherapy product candidate, GP2, through clinical trials aimed at preventing breast cancer recurrence. The company focuses on research and development to establish the efficacy and safety of its treatments, which could lead to commercialization and partnerships with other healthcare entities.
Additional Information
Greenwich LifeSciences is positioned within the biopharmaceutical sector, contributing to advancements in personalized medicine and cancer treatments. Its innovative approaches could significantly improve the prognosis for breast cancer patients, making it a key player in the medical sciences community.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
4
CEO
Mr. Snehal S. Patel
Country
United States
IPO Year
2020
Website
greenwichlifesciences.comGreenwich LifeSciences Inc. (GLSI) Latest News & Analysis
Latest News
Greenwich LifeSciences Provides Global Update on FLAMINGO-01, Screening Over 1,000 Patients to Date
4 days ago
Quick Summary
Greenwich LifeSciences (Nasdaq: GLSI) has screened over 1,000 patients in its Phase III trial FLAMINGO-01 for GLSI-100, targeting breast cancer recurrence, with 140 active sites globally.
Why It Matters
Greenwich LifeSciences' progress in screening patients for its Phase III trial indicates strong momentum, which could enhance investor confidence and affect stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
3 Stocks to Buy for a Volatile End to 2025
28 days ago
Quick Summary
Traders anticipate the Santa Claus Rally as 2025 approaches its final months, a trend often seen in markets during the holiday season.
Why It Matters
The Santa Claus Rally historically boosts stock prices in late December, signaling potential gains for investors in year-end trading strategies.
Source: InvestorPlace
Market Sentiment:
Positive
Quick Summary
Greenwich LifeSciences (Nasdaq: GLSI) has expanded its Phase III FLAMINGO-01 clinical trial for GLSI-100, an immunotherapy for breast cancer, to Austria.
Why It Matters
The expansion of Greenwich LifeSciences' Phase III trial indicates growth potential and increased investor confidence in its immunotherapy, potentially impacting stock performance positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Greenwich LifeSciences (Nasdaq: GLSI) has expanded its Phase III FLAMINGO-01 clinical trial for GLSI-100, an immunotherapy for breast cancer, to Portugal.
Why It Matters
The expansion of Greenwich LifeSciences' clinical trial to Portugal could enhance data diversity and increase the trial's robustness, potentially boosting investor confidence in the drug's efficacy and market potential.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Greenwich LifeSciences (Nasdaq: GLSI) announced the expansion of its Phase III FLAMINGO-01 clinical trial for GLSI-100, an immunotherapy for breast cancer recurrences, to Belgium.
Why It Matters
Greenwich LifeSciences expanding its Phase III trial to Belgium signals potential growth and increased market interest in GLSI-100, impacting stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Greenwich LifeSciences (Nasdaq: GLSI) is expanding its Phase III FLAMINGO-01 clinical trial for GLSI-100, an immunotherapy to prevent breast cancer recurrences, to Ireland.
Why It Matters
The expansion of Greenwich LifeSciences' clinical trial to Ireland signals potential for broader data collection and validation, enhancing the company's growth prospects and attractiveness to investors.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About GLSI Stock
What is Greenwich LifeSciences Inc.'s (GLSI) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Greenwich LifeSciences Inc. (GLSI) has a median price target of $45.00. The highest price target is $45.00 and the lowest is $45.00.
Is GLSI stock a good investment in 2026?
According to current analyst ratings, GLSI has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $8.94. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for GLSI stock?
Wall Street analysts predict GLSI stock could reach $45.00 in the next 12 months. This represents a 403.4% increase from the current price of $8.94. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Greenwich LifeSciences Inc.'s business model?
Greenwich LifeSciences generates revenue by advancing its immunotherapy product candidate, GP2, through clinical trials aimed at preventing breast cancer recurrence. The company focuses on research and development to establish the efficacy and safety of its treatments, which could lead to commercialization and partnerships with other healthcare entities.
What is the highest forecasted price for GLSI Greenwich LifeSciences Inc.?
The highest price target for GLSI is $45.00 from at , which represents a 403.4% increase from the current price of $8.94.
What is the lowest forecasted price for GLSI Greenwich LifeSciences Inc.?
The lowest price target for GLSI is $45.00 from at , which represents a 403.4% increase from the current price of $8.94.
What is the overall GLSI consensus from analysts for Greenwich LifeSciences Inc.?
The overall analyst consensus for GLSI is bullish. Out of 2 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $45.00.
How accurate are GLSI stock price projections?
Stock price projections, including those for Greenwich LifeSciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 4:33 PM UTC